Just got a phone interview# Environmental - 环境科学与工程
g*d
1 楼
OAP 旗下 Journal of Drug Resistant Pathogen Research，无分非SCI哦，稿件情况
如下：
Title: In Vitro Activity of Iclaprim Against Methicillin-Resistant
Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid or Vancomycin
Abstract:
Iclaprim is a novel bacterial dihydrofolate reductase inhibitor in Phase 3
clinical development for the treatment of acute bacterial skin and skin
structure infections and hospital acquired bacterial pneumonia caused by
Gram-positve bacteria. Daptomycin, linezolid and vancomycin are commonly
used antibiotic for these indications. With increase selective pressure to
these generic antibiotics, outbreaks of bacterial resistance to these
antibiotics have been reported. This in vitro study evaluated the activity
of iclaprim against methicillin-resistant Staphylococcus aureus (MRSA)
isolates, which were also not susceptible to daptomycin, linezolid or
vancomycin. Iclaprim had an MIC ≤1 μg/ml to the majority of MRSA isolates
that were nonsusceptible to daptomycin (5 of 7 [71.4%]), linezolid (26 of 26
[100%]), or vancomycin (19 of 28 [66.7%]). In time-kill curves analyses,
iclaprim demonstrated ≥3 log10 reduction in CFU/mL at 4-8 hours for tested
strains and isolates nonsusceptible to linezolid or vancomycin. Together
these data support the use of iclaprim in serious infections caused by MRSA
nonsusceptible to daptomycin, linezolid or vancomycin.
感兴趣站内回复，注明名字（拼音，last name），邮箱，研究领域或google/
researchgate profile 链接，谢谢
如下：
Title: In Vitro Activity of Iclaprim Against Methicillin-Resistant
Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid or Vancomycin
Abstract:
Iclaprim is a novel bacterial dihydrofolate reductase inhibitor in Phase 3
clinical development for the treatment of acute bacterial skin and skin
structure infections and hospital acquired bacterial pneumonia caused by
Gram-positve bacteria. Daptomycin, linezolid and vancomycin are commonly
used antibiotic for these indications. With increase selective pressure to
these generic antibiotics, outbreaks of bacterial resistance to these
antibiotics have been reported. This in vitro study evaluated the activity
of iclaprim against methicillin-resistant Staphylococcus aureus (MRSA)
isolates, which were also not susceptible to daptomycin, linezolid or
vancomycin. Iclaprim had an MIC ≤1 μg/ml to the majority of MRSA isolates
that were nonsusceptible to daptomycin (5 of 7 [71.4%]), linezolid (26 of 26
[100%]), or vancomycin (19 of 28 [66.7%]). In time-kill curves analyses,
iclaprim demonstrated ≥3 log10 reduction in CFU/mL at 4-8 hours for tested
strains and isolates nonsusceptible to linezolid or vancomycin. Together
these data support the use of iclaprim in serious infections caused by MRSA
nonsusceptible to daptomycin, linezolid or vancomycin.
感兴趣站内回复，注明名字（拼音，last name），邮箱，研究领域或google/
researchgate profile 链接，谢谢
